Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.ImmunoGen reports favorable data from Phase I multiple myeloma study
The findings presented are from a Phase I, dose-escalation clinical trial that evaluates the TAP compound IMGN901 used as a single agent for the treatment of multiple myeloma
The findings presented are from a Phase I, dose-escalation clinical trial that evaluates the TAP compound IMGN901 used as a single agent for the treatment of multiple myeloma
Study results showed that menadione was well tolerated at all doses tested. The open-label, modified dose-escalation study assessed the bioavailability, safety and tolerability of three concentrations (0.05%, 0.1%
Roche has also selected an additional exclusive target under the existing license and collaboration agreement. Under the terms of the agreement, Roche will pay Halozyme for exclusive, global
This study of GRN163L as a single agent is one of six ongoing clinical trials recruiting from 18 US medical centers examining the safety, tolerability, pharmacokinetics and pharmacodynamics
These results, which confirm the findings from the two previous Phase III trials, showed that milnacipran demonstrated a highly statistically significant difference to placebo in responder analyses based
The study involved elderly patients with acute myeloid leukemia (AML), who often have limited options due to comorbidities and are typically considered ineligible for standard induction chemotherapy. Data
GDC-0449 will be evaluated in approximately 100 patients with ovarian cancer in second or third complete remission in a randomized, placebo-controlled, double-blind, multi-center Phase II trial. Patients will
Tetrabenazine will be marketed as Nitoman in Spain by Cambridge’s marketing partner UCB upon successful completion of all related procedures. It has been approved for the treatment of
Results presented demonstrated that p110, whose expression under normal conditions is largely restricted to leukocytes, was highly expressed in more than 90% of hematologic cancer cell lines, including
Dapagliflozin, one of two investigational drugs under joint development by the companies, is currently being studied in Phase III clinical trials in several countries, including the US, to